| 1 |
34921503 | Inhibition of TRIM32 by ibr-7 treatment sensitizes pancreatic cancer cells to gemcitabine via mTOR/p70S6K pathway. | 2022 Jan |
1 |
| 2 |
35057550 | Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway. | 2022 Jan 15 |
1 |
| 3 |
35218764 | Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways. | 2022 May 1 |
2 |
| 4 |
35406478 | Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins. | 2022 Mar 27 |
1 |
| 5 |
33430324 | Water Soluble Iron-Based Coordination Trimers as Synergistic Adjuvants for Pancreatic Cancer. | 2021 Jan 7 |
1 |
| 6 |
33545231 | mTOR modulates resistance to gemcitabine in lung cancer in an MTORC2 dependent mechanism. | 2021 May |
4 |
| 7 |
33760142 | [Retracted] Anticancer activity of caffeic acid n‑butyl ester against A431 skin carcinoma cell line occurs via induction of apoptosis and inhibition of the mTOR/PI3K/AKT signaling pathway. | 2021 May |
2 |
| 8 |
33849427 | Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling. | 2021 Apr 13 |
1 |
| 9 |
34119916 | Combination of Gemcitabine and Thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer/T-cell lymphoma. | 2021 Sep |
1 |
| 10 |
34416437 | The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy. | 2021 Sep |
1 |
| 11 |
32654071 | Inhibition of autophagy by chloroquine enhances the antitumor activity of gemcitabine for gallbladder cancer. | 2020 Aug |
2 |
| 12 |
32819590 | GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway. | 2020 Sep 3 |
1 |
| 13 |
31354292 | Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment. | 2019 |
4 |
| 14 |
31841183 | Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway. | 2019 Dec |
4 |
| 15 |
29575133 | Gemcitabine induces apoptosis and autophagy via the AMPK/mTOR signaling pathway in pancreatic cancer cells. | 2018 Sep |
1 |
| 16 |
30416856 | Monepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer: in vitro and in vivo studies. | 2018 |
1 |
| 17 |
30419950 | LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. | 2018 Nov 12 |
1 |
| 18 |
30662800 | Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer. | 2018 |
1 |
| 19 |
28165150 | Everolimus Inhibits Growth of Gemcitabine-Resistant Pancreatic Cancer Cells via Induction of Caspase-Dependent Apoptosis and G2 /M Arrest. | 2017 Sep |
3 |
| 20 |
29018223 | Mechanistic Evaluation and Translational Signature of Gemcitabine-induced Chemoresistance by Quantitative Phosphoproteomics Analysis with iTRAQ Labeling Mass Spectrometry. | 2017 Oct 10 |
1 |
| 21 |
27235118 | mTOR inhibitors in urinary bladder cancer. | 2016 Sep |
2 |
| 22 |
25344906 | Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer. | 2015 Apr |
1 |
| 23 |
25586480 | Sirolimus plus gemcitabine: a new therapeutic combination for resistant sarcomas? | 2015 Mar |
1 |
| 24 |
26085897 | Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature. | 2015 Mar-Apr |
2 |
| 25 |
26500758 | Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma. | 2015 |
1 |
| 26 |
24654937 | Identification of new mechanisms of cellular response to chemotherapy by tracking changes in post-translational modifications by ubiquitin and ubiquitin-like proteins. | 2014 May 2 |
1 |
| 27 |
24804820 | The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells. | 2014 Jul |
1 |
| 28 |
24902539 | Phenoxodiol enhances the antitumor activity of gemcitabine in gallbladder cancer through suppressing Akt/mTOR pathway. | 2014 Nov |
1 |
| 29 |
24959297 | Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma. | 2014 Jul |
1 |
| 30 |
24966685 | Gemcitabine resistance in breast cancer cells regulated by PI3K/AKT-mediated cellular proliferation exerts negative feedback via the MEK/MAPK and mTOR pathways. | 2014 |
1 |
| 31 |
25003665 | Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours. | 2014 Aug 26 |
1 |
| 32 |
22488590 | Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells. | 2013 Sep |
1 |
| 33 |
23579097 | BLU enhances the effects of anti-angiogenic activity in combination with gemcitabine-based chemotherapeutic agents. | 2013 Jul |
1 |
| 34 |
22406590 | First-line treatment of metastatic pancreatic cancer. | 2012 Mar 10 |
1 |
| 35 |
22532602 | CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis. | 2012 Jul |
1 |
| 36 |
22726648 | Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. | 2012 Dec |
4 |
| 37 |
22903553 | sMEK1 enhances gemcitabine anti-cancer activity through inhibition of phosphorylation of Akt/mTOR. | 2012 Oct |
2 |
| 38 |
20460539 | MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. | 2010 Jun 1 |
1 |
| 39 |
19047305 | Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. | 2009 Jan 10 |
2 |
| 40 |
18251175 | Rapamycin enhances the anti-tumor effect of gemcitabine in pancreatic cancer cells. | 2007 Oct-Nov |
1 |